Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18818363 | TOPICAL COMPOSITION FOR IMPROVED HEALING OF OPEN WOUNDS | August 2024 | April 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18624804 | Personal Care Formulations | April 2024 | April 2025 | Allow | 12 | 1 | 0 | No | No |
| 18435678 | EFLORNITHINE AND SULINDAC, FIXED DOSE COMBINATION FORMULATION | February 2024 | March 2025 | Allow | 13 | 1 | 0 | Yes | No |
| 18397626 | PROCESS OF MAKING NANOEMULSION | December 2023 | January 2025 | Allow | 12 | 1 | 0 | No | No |
| 18386560 | 2-BENZO-[3,4-B] QUINOLINO-{B,G]INDENO [1',2':3,4] FLUORENO-[1,2-D] OXONINE-5,11,16,21-TETRAONE AS AN ANTIMICROBIAL COMPOUND | November 2023 | March 2024 | Allow | 4 | 0 | 1 | No | No |
| 18386579 | 3-(4-BROMOPHENYL)-5-((2-ISOPROPYL-5-METHYLPHENOXY)METHYL)-1,2,4-OXADIAZOLE AS AN ANTI-CANCER AND ANTIMICROBIAL COMPOUND | November 2023 | August 2024 | Allow | 9 | 2 | 1 | No | No |
| 18493990 | COSMETIC COMPOSITIONS, KITS THEREOF, AND METHODS FOR MAKING AND USING THE SAME | October 2023 | June 2024 | Allow | 8 | 0 | 0 | Yes | No |
| 18365724 | TRANSDERMAL DELIVERY SYSTEM INCLUDING AN INTERFACE MEDIATOR | August 2023 | June 2025 | Allow | 22 | 1 | 1 | Yes | No |
| 18357927 | INTRANASAL DELIVERY OF OLANZAPINE BY PRECISION OLFACTORY DEVICE | July 2023 | January 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18345029 | DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION | June 2023 | July 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18336431 | Silk-Based Moisturizer Compositions and Methods Thereof | June 2023 | June 2025 | Allow | 24 | 2 | 0 | No | No |
| 18334667 | PUTRESCINE TOPICAL BARRIER FORMULATION | June 2023 | July 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18327267 | TOPICAL COMPOSITION COMPRISED OF COD LIVER OIL FOR TREATING WOUNDS AND SKIN DISORDERS | June 2023 | September 2024 | Allow | 16 | 3 | 0 | Yes | No |
| 18327278 | TOPICAL COMPOSITION COMPRISED OF COD LIVER OIL FOR TREATING WOUNDS AND SKIN DISORDERS | June 2023 | September 2024 | Allow | 15 | 3 | 0 | Yes | No |
| 18124128 | COMPOUND AND METHOD FOR TREATING DISEASES AND DISORDERS | March 2023 | May 2025 | Abandon | 26 | 3 | 0 | No | No |
| 18123268 | Fast Release Benzoic Acid In Feed | March 2023 | July 2024 | Abandon | 16 | 2 | 0 | No | No |
| 18121576 | STEROIDAL COMPOSITIONS AND METHOD OF MAKING AND USE | March 2023 | July 2024 | Allow | 17 | 2 | 0 | Yes | No |
| 18177720 | POLYGLUTAMIC ACID COMPOSITIONS AND METHODS OF USING | March 2023 | April 2025 | Allow | 25 | 5 | 0 | Yes | No |
| 18115008 | TARGETED GASTROINTESTINAL TRACT DELIVERY OF PROBIOTIC ORGANISMS AND/OR THERAPEUTIC AGENTS | February 2023 | July 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18112635 | SKIN TREATMENT METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY OF ACTIVE AGENTS | February 2023 | February 2024 | Allow | 12 | 2 | 0 | Yes | No |
| 18171070 | TASTE-MASKING ORAL FORMULATIONS OF FASUDIL | February 2023 | July 2024 | Allow | 17 | 4 | 0 | Yes | No |
| 18106684 | NATURAL POLYMER-BASED TISSUE ADHESIVE WITH HEALING-PROMOTING PROPERTIES | February 2023 | June 2024 | Allow | 16 | 2 | 0 | No | No |
| 18149804 | FOOD GRADE WHITENING AGENTS AND USES THEREOF | January 2023 | May 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18056981 | TOPICAL COMPOSITION FOR IMPROVED HEALING OF OPEN WOUNDS | November 2022 | August 2024 | Abandon | 21 | 1 | 1 | No | No |
| 18055494 | EFLORNITHINE AND SULINDAC, FIXED DOSE COMBINATION FORMULATION | November 2022 | November 2023 | Allow | 12 | 2 | 0 | No | No |
| 17923076 | AN ANTIMICROBIAL COMPOSITION FOR TACKLING MALODOUR | November 2022 | May 2025 | Allow | 31 | 1 | 0 | No | No |
| 17970160 | KIT AND NEW METHOD OF TREATMENT FOR SKIN BASAL CELL AND SQUAMOUS CELL CARCINOMA | October 2022 | July 2023 | Allow | 8 | 1 | 1 | No | No |
| 17967470 | COMPOSITIONS AND METHODS FOR TREATMENT OF SKIN INFECTIONS | October 2022 | July 2023 | Allow | 9 | 1 | 0 | No | No |
| 17939396 | POWDERED FORMULATIONS OF CROMOLYN SODIUM AND IBUPROFEN | September 2022 | January 2024 | Abandon | 16 | 1 | 0 | No | No |
| 17902646 | COSMETIC FORMULATION | September 2022 | March 2024 | Abandon | 19 | 3 | 0 | Yes | No |
| 17876700 | DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION | July 2022 | August 2023 | Abandon | 12 | 1 | 0 | No | No |
| 17877005 | Water-soluble Unidirectional Moisture Transport Traditional Chinese Medicine Facial Mask and Preparation thereof | July 2022 | April 2024 | Allow | 21 | 2 | 1 | Yes | No |
| 17871111 | Personal Care Compositions Incorporating Natural Benefit Agents and Methods for the Same | July 2022 | May 2025 | Abandon | 34 | 4 | 0 | No | No |
| 17758315 | ORAL SOLID CANNABINOID OIL COMPOSITION FOR TREATING GASTROINTESTINAL DISORDERS | July 2022 | August 2024 | Allow | 26 | 1 | 0 | No | No |
| 17848981 | COMPOSITION FOR PREVENTING AND TREATING INFLAMMATORY BOWEL DISEASE INCLUDING PUER TEA EXTRACT | June 2022 | June 2025 | Allow | 36 | 4 | 0 | Yes | Yes |
| 17831333 | TOPICAL COMPOSITION FOR HOMEOSTATIC DELIVERY OF NITRIC OXIDE AND USES THEREOF | June 2022 | June 2024 | Allow | 24 | 2 | 0 | Yes | No |
| 17751883 | COSMETIC PRODUCT COMPRISING A COSMETIC COMPOSITION CONTAINED IN AN APPLICATOR | May 2022 | June 2024 | Abandon | 25 | 2 | 0 | No | No |
| 17746713 | COMPOSITION OF TANNIC ACID AND VITAMIN D AND METHODS OF USE | May 2022 | October 2023 | Abandon | 17 | 1 | 0 | No | No |
| 17746555 | METHOD FOR WHITENING SKIN USING COMPOSITION FOR SKIN WHITENING | May 2022 | February 2025 | Allow | 33 | 4 | 0 | Yes | No |
| 17744685 | PHARMACEUTICAL COMPOSITIONS OF BERBERINE WITH EPA AND DHA, AND METHODS THEREOF | May 2022 | November 2023 | Allow | 18 | 2 | 0 | No | No |
| 17743895 | Personal Care Formulations | May 2022 | December 2023 | Allow | 19 | 2 | 0 | No | No |
| 17743537 | WET WIPES WITH A CELLULOSIC SUBSTRATE AND GENTLE LOTION | May 2022 | December 2023 | Allow | 19 | 2 | 0 | No | No |
| 17743529 | WET WIPES WITH A CELLULOSIC SUBSTRATE AND GENTLE LOTION | May 2022 | January 2024 | Allow | 20 | 2 | 0 | No | No |
| 17739246 | Hydrogel-Fabric Composite For Cosmetic Applications | May 2022 | March 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17755408 | OIL-IN-WATER TYPE COMPOSITION | April 2022 | June 2025 | Allow | 38 | 2 | 0 | No | No |
| 17732162 | COMPOSITION AND METHOD FOR ODOR CONTROL | April 2022 | August 2023 | Allow | 16 | 1 | 0 | No | No |
| 17730305 | STEROIDAL COMPOSITIONS AND METHOD OF MAKING AND USE | April 2022 | February 2023 | Allow | 10 | 2 | 0 | No | No |
| 17728522 | ANTI-AGING AND SKIN TONE LIGHTENING COMPOSITIONS AND METHODS FOR SAME | April 2022 | March 2025 | Abandon | 34 | 4 | 0 | No | No |
| 17717868 | Personal Care Composition | April 2022 | June 2023 | Allow | 14 | 1 | 0 | No | No |
| 17766487 | ORAL CARE COMPOSITION COMPRISING CUTTLEFISH BONE POWDER | April 2022 | May 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17763236 | TREATMENT OF SKIN DISORDERS WITH TOPICAL COMBINATION COMPOSITIONS COMPRISING TAPINAROF AND AN ADDITIONAL AHR ACTIVATOR | March 2022 | May 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17761792 | COMPOSITIONS AND METHODS FOR RESTORING OR INCREASING TISSUE PERFUSION | March 2022 | March 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 17638713 | COMPOSITION, PROCESS AND KIT FOR SEMI-PERMANENT STRAIGHTENING AND CURLING OF KERATIN FIBERS | February 2022 | March 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17613448 | METHOD FOR STABILIZING HUMIDITY-SENSITIVE PHARMACEUTICAL SUBSTANCE AND STABILIZED PREPARATION THEREOF | February 2022 | February 2023 | Allow | 15 | 3 | 0 | Yes | No |
| 17674728 | PRODUCING ATP AND IMPROVING MITOCHONDRIAL FUNCTION IN A MAMMAL USING A POLY-OXYGENATED METAL HYDROXIDE | February 2022 | April 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17666577 | COMPOSITION FOR STIMULATING MUSCLE GROWTH, REPAIR, AND MAINTENANCE | February 2022 | April 2023 | Allow | 14 | 1 | 0 | No | No |
| 17666181 | COMPOSITIONS AND METHODS FOR TREATMENT OF SKIN INFECTIONS | February 2022 | August 2022 | Allow | 6 | 1 | 0 | Yes | No |
| 17632959 | HIGH PERFORMANCE ANTIMICROBIAL COMPOSITION | February 2022 | March 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17586618 | DEFINED DOSE CANNABIS POD | January 2022 | May 2025 | Abandon | 40 | 2 | 1 | No | No |
| 17576202 | USE OF NUTRITIONAL COMPOSITIONS HAVING A LOW PROTEIN AMOUNT | January 2022 | April 2024 | Allow | 27 | 2 | 0 | Yes | No |
| 17574511 | INTRANASAL DELIVERY OF OLANZAPINE BY PRECISION OLFACTORY DEVICE | January 2022 | April 2023 | Allow | 15 | 1 | 0 | Yes | No |
| 17621930 | SKINCARE COMPOSITIONS | December 2021 | December 2024 | Allow | 36 | 2 | 0 | Yes | No |
| 17559143 | NANOPARTICLES AND METHODS FOR PREPARATION THEREOF | December 2021 | July 2024 | Abandon | 31 | 2 | 0 | No | No |
| 17548232 | PARENTERAL FORMULATIONS | December 2021 | April 2024 | Allow | 28 | 2 | 0 | Yes | No |
| 17534500 | Bijels And Methods Of Making The Same | November 2021 | March 2025 | Allow | 40 | 3 | 0 | Yes | No |
| 17530002 | METHOD FOR TREATING CANCER WITH A NANOFORMULATION | November 2021 | April 2023 | Allow | 17 | 1 | 0 | No | No |
| 17528689 | Enteric Coated Multiparticulate Compositions With A Proteinaceous Subcoat | November 2021 | July 2023 | Allow | 20 | 1 | 0 | No | No |
| 17510162 | HYDROGEL PATCH INCLUDING ADDITIVE SOLUTION ADJUSTABLE FOR ITS SYNERESIS PATTERN AND METHOD OF MANUFACTURING THE COMPOSITION | October 2021 | September 2024 | Allow | 35 | 0 | 1 | Yes | No |
| 17602571 | GEL CLEANSING AGENT | October 2021 | July 2024 | Allow | 34 | 1 | 0 | No | No |
| 17600852 | HAIR DYE | October 2021 | April 2024 | Allow | 31 | 0 | 0 | No | No |
| 17600582 | DEODORISING COMPOSITION | September 2021 | February 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17449211 | DILUTABLE FORMULATIONS OF CANNABINOIDS AND PROCESSES FOR THEIR PREPARATION | September 2021 | July 2023 | Allow | 21 | 1 | 0 | Yes | No |
| 17598378 | COSMETIC COMPOSITION | September 2021 | March 2025 | Allow | 41 | 2 | 0 | Yes | No |
| 17478395 | PEDIATRIC DOSAGE FORMS, METHODS OF MAKING AND USING | September 2021 | June 2024 | Allow | 33 | 2 | 0 | Yes | Yes |
| 17472823 | CANNABINOID COMPOSITION AND PROCESSES OF MANUFACTURE | September 2021 | June 2024 | Abandon | 33 | 3 | 0 | No | No |
| 17438881 | COSMETIC PRODUCT CONTAINING A MIXTURE OF SILICONES | September 2021 | October 2024 | Abandon | 37 | 1 | 0 | No | No |
| 17438362 | Novel Application for Inhibitors of cAMP Efflux in Body Care | September 2021 | January 2024 | Allow | 28 | 1 | 0 | Yes | No |
| 17593127 | POTASSIUM-BINDING AGENTS FOR USE IN HEMODIALYSIS PATIENTS | September 2021 | April 2025 | Abandon | 43 | 2 | 0 | No | No |
| 17467272 | ALCOHOL COMPOSITION | September 2021 | April 2025 | Allow | 43 | 3 | 0 | Yes | No |
| 17310990 | Personal Care Compositions | September 2021 | August 2024 | Allow | 36 | 3 | 0 | Yes | No |
| 17436250 | INDUCING CASPASE ACTIVITY | September 2021 | December 2024 | Allow | 39 | 2 | 0 | No | No |
| 17434865 | COMPOSITION IN MICRO-ENCAPSULATED FORM, BASED ON N-BUTYRICACID OR DERIVATIVES THEREOF, FOR TREATING CROHNS DISEASE OR ULCERATIVE RECTAL COLITIS | August 2021 | November 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17402131 | MEBENDAZOLE POLYMORPH FOR TREATMENT AND PREVENTION OF TUMORS | August 2021 | December 2023 | Abandon | 28 | 2 | 1 | No | No |
| 17429683 | POULTICE | August 2021 | December 2023 | Allow | 28 | 2 | 0 | No | No |
| 17396766 | ANTIBACTERIAL, DEODORIZATION, EASING OF ACNE AND ATOPY OR SKIN CALMING-FUNCTIONAL COMPOSITION FOR Y-ZONE CLEANLINESS CONTAINING QUERCUS ACUTISSIMA SAP AND ZINC RICINOLEATE | August 2021 | July 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17375588 | TOPICAL COMPOSITION USING A TWO-PART FORM FACTOR | July 2021 | November 2023 | Abandon | 28 | 2 | 1 | Yes | No |
| 17421978 | PHARMACEUTICAL DELIVERY COMPOSITIONS AND USES THEREOF | July 2021 | April 2025 | Allow | 45 | 4 | 1 | Yes | No |
| 17368724 | METHOD FOR PREVENTING OR TREATING INFECTION OF RESPIRATORY VIRUS UTILIZING GOLD NANOPARTICLES | July 2021 | May 2022 | Abandon | 11 | 2 | 0 | No | No |
| 17359991 | WATER-SOLUBLE FILM AND PACKAGE | June 2021 | October 2024 | Allow | 39 | 1 | 0 | Yes | No |
| 17358616 | Cardiovascular Prostheses | June 2021 | October 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17416925 | HAIR CARE COMPOSITION | June 2021 | August 2024 | Allow | 38 | 1 | 0 | Yes | No |
| 17416204 | COSMETIC COMPOSITION FOR KERATIN FIBRES COMPRISING A FATTY ACID ESTER | June 2021 | October 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17416167 | COSMETIC COMPOSITION FOR KERATIN FIBERS COMPRISING A FATTY ACID ESTER | June 2021 | October 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17415206 | PROCESS FOR TREATING KERATIN FIBERS USING A COMPOSITION COMPRISING A CARNITINE SALT OR CARNITINE DERIVATIVE SALT COMPRISING AN AROMATIC ORGANIC ANION | June 2021 | May 2025 | Allow | 47 | 2 | 1 | No | No |
| 17350088 | Hair conditioning composition with antimicrobial system | June 2021 | February 2024 | Allow | 32 | 3 | 0 | No | No |
| 17350478 | PHARMACEUTICAL GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | June 2021 | April 2022 | Allow | 10 | 2 | 0 | Yes | No |
| 17415602 | PROCESS FOR TREATING KERATIN FIBERS USING A COMPOSITION COMPRISING A CARNITINE SALT OR CARNITINE DERIVATIVE SALT COMPRISING AN ALIPHATIC DICARBOXYLIC ACID ANION | June 2021 | April 2025 | Allow | 46 | 2 | 1 | Yes | No |
| 17414781 | DYE COMPOSITION COMPRISING AT LEAST ONE POLYSACCHARIDE-TYPE POLYMER AND PROCESS FOR DYEING KERATIN FIBERS USING SAME | June 2021 | July 2025 | Abandon | 48 | 3 | 0 | No | No |
| 17414470 | HAIR CONDITIONING COMPOSITION FOR IMPROVED DEPOSITION | June 2021 | May 2025 | Allow | 47 | 3 | 0 | Yes | No |
| 17414181 | DEPOSITION SYSTEM FOR HAIR | June 2021 | December 2024 | Allow | 42 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHANG, KYUNG SOOK.
With a 21.1% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 18.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner CHANG, KYUNG SOOK works in Art Unit 1613 and has examined 770 patent applications in our dataset. With an allowance rate of 61.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 26 months.
Examiner CHANG, KYUNG SOOK's allowance rate of 61.3% places them in the 14% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by CHANG, KYUNG SOOK receive 2.38 office actions before reaching final disposition. This places the examiner in the 81% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by CHANG, KYUNG SOOK is 26 months. This places the examiner in the 59% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +40.1% benefit to allowance rate for applications examined by CHANG, KYUNG SOOK. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 23.3% of applications are subsequently allowed. This success rate is in the 22% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 34.6% of cases where such amendments are filed. This entry rate is in the 44% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 107.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 77% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 64.2% of appeals filed. This is in the 39% percentile among all examiners. Of these withdrawals, 64.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 54.2% are granted (fully or in part). This grant rate is in the 68% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.1% of allowed cases (in the 47% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.